Business Segments · D&A
BioPharma Systems — D&A
Becton, Dickinson and Company BioPharma Systems — D&A decreased by 20.6% to $27.00M in Q1 2026 compared to the prior quarter.
Analysis
How to read this metric
An increase often signals significant recent capital investment or the amortization of acquired intangible assets, while a decrease may indicate aging infrastructure or fully amortized assets.
Detailed definition
This metric reflects the non-cash expense allocated to the BioPharma Systems segment for the wear and tear of physical a...
Peer comparison
Similar to depreciation and amortization charges reported by peers in the medical device and pharmaceutical packaging industries.
Metric ID:
bdx_segment_biopharma_systems_depreciation_and_amortizationHistorical Data
4 periods
| Q4 '24 | Q1 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|
| Value | $31.00M | $32.00M | $34.00M | $27.00M |
| QoQ Change | — | +3.2% | +6.3% | -20.6% |
| YoY Change | — | — | +9.7% | -15.6% |
Range$27.00M – $34.00M
Avg YoY Growth-3.0%
Median YoY Growth-3.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's biopharma systems — d&a?
- Becton, Dickinson and Company (BDX) reported biopharma systems — d&a of $27.00M in Q1 2026.
- What does biopharma systems — d&a mean?
- The total non-cash expense related to the aging of physical and intangible assets within the BioPharma Systems segment.